Selected Grants
Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platform
ResearchAdvisor · Awarded by National Cancer Institute · 2022 - 2027Role of the NLRP3-NLRC5 Signaling Pathway in Melanoma Immune Evasion and Dormancy
ResearchCollaborator · Awarded by Department of Defense · 2024 - 2027Precision Medicine Trial Using MicroOrganoSpheres to Guide Care in Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by Mario Family Foundation · 2022 - 2025Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2025Dissecting the evolutionary landscape of treatment resistance in rectal cancer using patient-derived models.
ResearchCollaborator · Awarded by American Gastroenterological Association · 2022 - 2025Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platform
ResearchAdvisor · Awarded by National Cancer Institute · 2022 - 2027Role of the NLRP3-NLRC5 Signaling Pathway in Melanoma Immune Evasion and Dormancy
ResearchCollaborator · Awarded by Department of Defense · 2024 - 2027Precision Medicine Trial Using MicroOrganoSpheres to Guide Care in Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by Mario Family Foundation · 2022 - 2025Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2025Dissecting the evolutionary landscape of treatment resistance in rectal cancer using patient-derived models.
ResearchCollaborator · Awarded by American Gastroenterological Association · 2022 - 2025(R21) Microfluidic Droplet Organoids to Decipher the Tumor Heterogeneity in CRC of African Ancestry
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025Synthetic lethality by targeting the core senescent mechanism in lung cancer.
ResearchCollaborator · Awarded by National Institutes of Health · 2020 - 2025The role of ferroptosis in the metastatic ovarian cancer
ResearchCo Investigator · Awarded by Ovarian Cancer Research Alliance · 2022 - 2024Development of an Organoid/MicroOrganoid Biobank with matching TILs (Tumor Infiltrating Lymphocytes) to Correlate Response to Therapy
ResearchPrincipal Investigator · Awarded by Xilis, Inc. · 2020 - 2024Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2024Targeting KRAS (G12C) Mutant in Colorectal Cancer
ResearchPrincipal Investigator · Awarded by Amgen, Inc. · 2018 - 2024Therapeutic targeting of MESH1 in renal cell carcinoma
ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2023Global Measurements of Protein Folding Stability for Characterization of Aging and Disease
ResearchCollaborating Investigator · Awarded by National Institutes of Health · 2019 - 2023Inhibition of CaMKK2 sensitizes rectal cancers to radiation therapy
ResearchCollaborator · Awarded by National Institutes of Health · 2021 - 2022Therapeutic targeting of cystine addiction of renal cell carcinoma
ResearchCo Investigator · Awarded by Department of Defense · 2019 - 2022Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis
ResearchCo Investigator · Awarded by Department of Defense · 2018 - 2022Targeting tumor-specific apoptosis regulation in advanced ER+ breast cancer
ResearchCollaborator · Awarded by Department of Defense · 2019 - 2022Selectively targeting apoptosis in PIK3CA mutant colorectal cancers
ResearchCollaborator · Awarded by National Institutes of Health · 2016 - 2022Anonymous Donation
ResearchProject Leader · Awarded by Anonymous Trust · 2020 - 2022Medical Scientist Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1997 - 2022Understanding methionine metabolism and its therapeutic potential in cancer
ResearchAdvisor · Awarded by National Institutes of Health · 2019 - 2021Determining the Efficacy of Liposomal Gemcitabine in Patient Derived Xenografts (PDXs)
ResearchPrincipal Investigator · Awarded by FUJIFILM Pharmaceuticals U.S.A. · 2017 - 2019Identifying gene-environment interactions that confer metabolic vulnerabilities in cancer
FellowshipCollaborator · Awarded by National Institutes of Health · 2018 - 2019Targeting differential apoptosis regulation in triple negative breast cancer
ResearchCollaborator · Awarded by Department of Defense · 2016 - 2019Targeting the TK1 receptor in colorectal and lung PDX using CarT cell and Motorcar cell
ResearchPrincipal Investigator · Awarded by Thunder Biotech · 2017 - 2019Role of the Stroma in Fibrolamellar Hepatocellular Carcinoma
ResearchInvestigator · Awarded by Fibrolamellar Cancer Foundation · 2016 - 2019Using bacterial CRISPR/Cas endonucleases to selectively eliminate HPV-transformed cells in vivo
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2017Targeting Calreticulin in Colorectal Cancer Liver Metastasis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2017Development and Validation of Novel Therapeutic Targets in Anal Cancer
ResearchPrincipal Investigator · Awarded by The Farrah Fawcett Foundation · 2015 - 2016Aptamer Targeted Drug and Toxin Delivery to Prostate Cancer
FellowshipCollaborator · Awarded by Department of Defense · 2014 - 2016A Platform for Real-time Drug Profiling of Patient-Derived Melanomas
FellowshipCollaborator · Awarded by National Institutes of Health · 2014 - 2016In Vivo Selection of Tumor-Specific RNA Binding Motifs
ResearchCollaborator · Awarded by National Institutes of Health · 2011 - 2015Administrative Supplement for Recruitment of New Faculty
ResearchProject PI · Awarded by National Cancer Institute · 2009 - 2011External Relationships
- AccuBeing LLC
- Xilis, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.